Skip to main content
Clinical Trials/IRCT20170702034844N7
IRCT20170702034844N7
Recruiting
Phase 3

Comparison of buprenorphine and methadone maintenance treatments in prison: a randomized controlled trial

Faran Shimi Pharmaceutical Company0 sites100 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
Faran Shimi Pharmaceutical Company
Enrollment
100
Status
Recruiting
Last Updated
5 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
5 years ago
Study Type
Interventional
Sex
Male

Investigators

Sponsor
Faran Shimi Pharmaceutical Company

Eligibility Criteria

Inclusion Criteria

  • Diagnosis of moderate to severe opioid use disorder based on DSM\-5
  • Continuous consumption of illegal opioids in the past month prior to incarceration
  • Age 18 to 50 years
  • Informed written consent to enter the study
  • Conviction period more than 6 months

Exclusion Criteria

  • Concurrent diagnosis of other substance use disorders (except tobacco)
  • Uncontrolled severe psychiatric disorders including serious suicidality or psychosis based on a study physician's diagnosis
  • Severe and uncontrolled physical conditions including unstable angina, liver failure and a history of myocardial infarction during last month based on physician' s diagnosis and laboratory evaluations
  • Inability to understand the study protocol or respond to study assessments
  • More than three times raise of liver enzymes

Outcomes

Primary Outcomes

Not specified

Similar Trials